Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer
While cancer immunotherapy has gained much deserved attention in recent years, many areas regarding the optimization of such modalities remain unexplored, including the development of novel approaches and the strategic combination of therapies that target multiple aspects of the cancer-immunity cycl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier España
2018-09-01
|
| Series: | Clinics |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200318&lng=en&tlng=en |
| _version_ | 1811330856001732608 |
|---|---|
| author | Bryan E. Strauss Gissele Rolemberg Oliveira Silva Igor de Luna Vieira Otto Luiz Dutra Cerqueira Paulo Roberto Del Valle Ruan Felipe Vieira Medrano Samir Andrade Mendonça |
| author_facet | Bryan E. Strauss Gissele Rolemberg Oliveira Silva Igor de Luna Vieira Otto Luiz Dutra Cerqueira Paulo Roberto Del Valle Ruan Felipe Vieira Medrano Samir Andrade Mendonça |
| author_sort | Bryan E. Strauss |
| collection | DOAJ |
| description | While cancer immunotherapy has gained much deserved attention in recent years, many areas regarding the optimization of such modalities remain unexplored, including the development of novel approaches and the strategic combination of therapies that target multiple aspects of the cancer-immunity cycle. Our own work involves the use of gene transfer technology to promote cell death and immune stimulation. Such immunogenic cell death, mediated by the combined transfer of the alternate reading frame (p14ARF in humans and p19Arf in mice) and the interferon-β cDNA in our case, was shown to promote an antitumor immune response in mouse models of melanoma and lung carcinoma. With these encouraging results, we are now setting out on the road toward translational and preclinical development of our novel immunotherapeutic approach. Here, we outline the perspectives and challenges that we face, including the use of human tumor and immune cells to verify the response seen in mouse models and the incorporation of clinically relevant models, such as patient-derived xenografts and spontaneous tumors in animals. In addition, we seek to combine our immunotherapeutic approach with other treatments, such as chemotherapy or checkpoint blockade, with the goal of reducing dosage and increasing efficacy. The success of any translational research requires the cooperation of a multidisciplinary team of professionals involved in laboratory and clinical research, a relationship that is fostered at the Cancer Institute of Sao Paulo. |
| first_indexed | 2024-04-13T16:10:16Z |
| format | Article |
| id | doaj.art-9e494274f77b4c3394d29735776f8fce |
| institution | Directory Open Access Journal |
| issn | 1980-5322 |
| language | English |
| last_indexed | 2024-04-13T16:10:16Z |
| publishDate | 2018-09-01 |
| publisher | Elsevier España |
| record_format | Article |
| series | Clinics |
| spelling | doaj.art-9e494274f77b4c3394d29735776f8fce2022-12-22T02:40:17ZengElsevier EspañaClinics1980-53222018-09-0173suppl 110.6061/clinics/2018/e479sS1807-59322018000200318Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transferBryan E. StraussGissele Rolemberg Oliveira SilvaIgor de Luna VieiraOtto Luiz Dutra CerqueiraPaulo Roberto Del ValleRuan Felipe Vieira MedranoSamir Andrade MendonçaWhile cancer immunotherapy has gained much deserved attention in recent years, many areas regarding the optimization of such modalities remain unexplored, including the development of novel approaches and the strategic combination of therapies that target multiple aspects of the cancer-immunity cycle. Our own work involves the use of gene transfer technology to promote cell death and immune stimulation. Such immunogenic cell death, mediated by the combined transfer of the alternate reading frame (p14ARF in humans and p19Arf in mice) and the interferon-β cDNA in our case, was shown to promote an antitumor immune response in mouse models of melanoma and lung carcinoma. With these encouraging results, we are now setting out on the road toward translational and preclinical development of our novel immunotherapeutic approach. Here, we outline the perspectives and challenges that we face, including the use of human tumor and immune cells to verify the response seen in mouse models and the incorporation of clinically relevant models, such as patient-derived xenografts and spontaneous tumors in animals. In addition, we seek to combine our immunotherapeutic approach with other treatments, such as chemotherapy or checkpoint blockade, with the goal of reducing dosage and increasing efficacy. The success of any translational research requires the cooperation of a multidisciplinary team of professionals involved in laboratory and clinical research, a relationship that is fostered at the Cancer Institute of Sao Paulo.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200318&lng=en&tlng=enMelanomaImmunotherapyImmunogenic Cell DeathTranslational MedicineViral Vectors |
| spellingShingle | Bryan E. Strauss Gissele Rolemberg Oliveira Silva Igor de Luna Vieira Otto Luiz Dutra Cerqueira Paulo Roberto Del Valle Ruan Felipe Vieira Medrano Samir Andrade Mendonça Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer Clinics Melanoma Immunotherapy Immunogenic Cell Death Translational Medicine Viral Vectors |
| title | Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer |
| title_full | Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer |
| title_fullStr | Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer |
| title_full_unstemmed | Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer |
| title_short | Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer |
| title_sort | perspectives for cancer immunotherapy mediated by p19arf plus interferon beta gene transfer |
| topic | Melanoma Immunotherapy Immunogenic Cell Death Translational Medicine Viral Vectors |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200318&lng=en&tlng=en |
| work_keys_str_mv | AT bryanestrauss perspectivesforcancerimmunotherapymediatedbyp19arfplusinterferonbetagenetransfer AT gisselerolembergoliveirasilva perspectivesforcancerimmunotherapymediatedbyp19arfplusinterferonbetagenetransfer AT igordelunavieira perspectivesforcancerimmunotherapymediatedbyp19arfplusinterferonbetagenetransfer AT ottoluizdutracerqueira perspectivesforcancerimmunotherapymediatedbyp19arfplusinterferonbetagenetransfer AT paulorobertodelvalle perspectivesforcancerimmunotherapymediatedbyp19arfplusinterferonbetagenetransfer AT ruanfelipevieiramedrano perspectivesforcancerimmunotherapymediatedbyp19arfplusinterferonbetagenetransfer AT samirandrademendonca perspectivesforcancerimmunotherapymediatedbyp19arfplusinterferonbetagenetransfer |